Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Actinic Keratosis

  • Author: James M Spencer, MD; Chief Editor: William D James, MD  more...
 
Updated: Apr 07, 2016
 

Practice Essentials

Actinic keratosis (AK) is a UV light–induced lesion of the skin that may progress to invasive squamous cell carcinoma. It is by far the most common lesion with malignant potential to arise on the skin. See the image below.

Actinic keratosis. Courtesy of Hon Pak, MD. Actinic keratosis. Courtesy of Hon Pak, MD.

See Nonmelanoma Skin Cancers You Need to Know and Can You Recognize Benign Skin Lesions From Cancerous Ones?, Critical Images slideshows, to help correctly identify various lesions.

Signs and symptoms

Actinic keratoses develop as follows:

  • The lesions begin as small, rough spots that are easier felt than seen and that have what is often described as a sandpaperlike texture [1]
  • With time, the lesions enlarge, usually becoming red and scaly
  • Most lesions are only 3-10 mm, but they may enlarge to several centimeters in size [1, 2, 3]

The typical patient with actinic keratoses is an elderly, fair-skinned, sun-sensitive person.[4] The lesions arise in areas of long-term sun exposure, including the face, ears, and, in men, bald scalp, as well as in the dorsal forearms and hands.[5, 6]

Patients may develop multiple lesions within a single anatomic area, to the extent that the lesions collide and produce confluent actinic keratosis over a relatively large area. The following variants can occur[7] :

  • Brown (pigmented actinic keratosis)
  • Atrophic
  • Bowenoid
  • Lichen planus–like
  • Exaggerated hyperkeratosis - Produces a hornlike projection, known as a cutaneous horn, above the skin surface

The image below is a typical depiction of actinic keratosis.

Erythematous, scaly lesions on the temple area, ty Erythematous, scaly lesions on the temple area, typical of actinic keratosis.

See Clinical Presentation for more detail.

Diagnosis

Histology

A skin biopsy is indicated to confirm the diagnosis and to rule out invasive squamous cell carcinoma for suspicious or more advanced lesions (ie, those with more pronounced hyperkeratosis, increased erythema, or induration or nodularity).[8, 9] A biopsy is also indicated for recurrent lesions or those that are unresponsive to therapy.

Actinic keratosis is characterized by dysplasia and architectural disorder of the epidermis, as follows[1] :

  • Abnormal keratinocytes of the basal layer that are variable in size and shape
  • Altered cellular polarity
  • Nuclear atypia
  • Hyperkeratosis and parakeratosis of the epidermis
  • Irregular acanthosis may be present

In general, hair follicles, sebaceous glands, and apocrine and eccrine ducts are not involved.[1]

Fluorescence

Fluorescence with the use of a photosensitizing drug (methyl ester of 5-aminolevulinic acid [ALA], a precursor of protoporphyrin) commonly used during photodynamic therapy (PDT) has been described as a diagnostic tool for actinic keratosis.[10] Areas of involvement, including occult areas of abnormal skin, emit a pink fluorescence with a Wood lamp or photodynamic therapy lamp.[10]

See Workup for more detail.

Management

Treatment consists of the following categories:

  • Medical therapy - including pharmacologic treatment and PDT
  • Surgical destruction of the lesion
  • Pharmacologic treatment

Medications approved by the US Food and Drug Administration (FDA) for the treatment of actinic keratosis include the following[11, 12, 13] :

  • Topical 5-fluorouracil (5-FU)
  • Imiquimod cream
  • Ingenol mebutate gel
  • Topical diclofenac gel

Photodynamic therapy

PDT uses a light-sensitizing compound that preferentially accumulates in actinic keratosis cells, where it can be activated by the appropriate wavelength of light. Delta-aminolevulinic acid is a component of the heme biosynthetic pathway that accumulates preferentially in dysplastic cells. Once inside these cells, it is enzymatically converted to protoporphyrin IX, a potent photosensitizer. With exposure to light of an appropriate wavelength, oxygen free radicals are generated and cell death results.[14]

Surgery

Types of surgery used in the eradication of actinic keratoses include the following[15, 16, 17] :

  • Cryosurgery
  • Curettage, shave excision, and conventional excision - For lesions suggestive of invasive cancer
  • Cosmetic resurfacing procedures - Including medium and deep chemical peels, dermabrasion, and ablative laser resurfacing

See Treatment and Medication for more detail.

Next

Background

Actinic keratosis (AK) is a UV light–induced lesion of the skin that may progress to invasive squamous cell carcinoma.[18, 19, 20] It is by far the most common lesion with malignant potential to arise on the skin. Actinic keratosis is seen in fair-skinned persons on skin areas that have had long-term sun exposure.[5] In Australia, the country with the highest skin cancer rate in the world, the prevalence of actinic keratosis among adults older than 40 years has been reported to range from 40-60%.[21]

The premalignant nature of actinic keratosis was recognized almost 100 years ago, and the name literally means thickened scaly growth (keratosis) caused by sunlight (actinic). In the United States, actinic keratosis represents the second most frequent reason for patients to visit a dermatologist.[22]

An actinic keratosis may follow 1 of 3 paths; it may regress, it may persist unchanged, or it may progress to invasive squamous cell carcinoma. The actual percentage that progress to invasive squamous cell carcinoma remains unknown, and estimates have varied from as low as 0.1% to as high as 10%.[18, 23]

In 2009, Criscione and colleagues conducted a study examining the progression of actinic keratoses to squamous cell carcinoma and basal cell carcinoma. The study examined 7784 actinic keratoses in a high-risk population and found that nearly 65% of primary squamous cell carcinomas and 36% of primary basal cell carcinomas arise from clinically diagnosed actinic keratoses. Furthermore, risk of progression of actinic keratosis to squamous cell carcinoma was 0.60% at 1 year and 2.57% at 4 years, which is 6-8 times more frequent than has been reported in some prior studies.

Although it is impossible to predict which individual lesion will follow which course, as most patients have many lesions, accessing risk becomes more significant and aids in tailoring treatments. Overall, actinic keratoses can be safely and effectively eradicated, and, therefore, therapy is warranted.

Previous
Next

Pathophysiology

Actinic keratoses arise on fair-skinned people in areas of long-term sun exposure, such as the face, ears, bald scalp, forearms, and backs of the hands.[5] However, they may occur on any area that is repeatedly exposed to the sun, such as the back, the chest, and the legs. Long-term UV light exposure is implicated as the cause from both epidemiologic observations and molecular analysis of tumor cells.[19, 5] Actinic keratosis frequency correlates with cumulative UV exposure.[5] Therefore, the frequency of actinic keratosis increases with each decade of life, is greater in residents of sunny countries closer to the equator, and is greater in persons with outdoor occupations.[5, 4] DNA analysis of the cells within actinic keratoses shows characteristic UV-induced mutations in key genes, including TP53 and deletion of the gene coding for p16 tumor suppressor protein.[19, 24, 25]

Clinically, actinic keratoses range from barely perceptible rough spots of skin to elevated, hyperkeratotic plaques several centimeters in diameter.[26] Most often, they appear as multiple discrete, flat or elevated, keratotic lesions. Lesions typically have an erythematous base covered by scale (hyperkeratosis).[26] They are usually 3-10 mm in diameter and gradually enlarge into broader, more elevated lesions.

Over time, actinic keratoses may develop into invasive squamous cell carcinoma; according to one study of almost 7000 patients, among the small percentage of actinic keratoses that progress into squamous cell carcinoma, the length of time for this transformation to occur was approximately 2 years.[27] Development of actinic keratoses may occur as early as the third or fourth decade of life in patients who live in areas of high solar radiation, are fair-skinned, and do not use sunscreen for photoprotection.[5] Usually, patients demonstrate a background of solar-damaged skin with telangiectasias, elastosis, and pigmented lentigines.[1]

In both histologic and molecular parameters, actinic keratoses share features with squamous cell carcinoma.[28] Actinic keratosis is an epidermal lesion characterized by aggregates of atypical, pleomorphic keratinocytes at the basal layer that may extend upwards to involve the granular and cornified layers.[28] The epidermis itself shows an abnormal architecture, with acanthosis, parakeratosis, and dyskeratosis. Cellular atypia is present, and the keratinocytes vary in size and shape; mitotic figures are present.[28] This presentation may resemble Bowen disease or carcinoma in situ, and the distinction between the 2 is a matter of degree (extent of the lesion) rather than differences in individual cells.[28]

Often, marked hyperkeratosis and areas of parakeratosis with loss of the granular layer are present. A dense inflammatory infiltrate is usually present. The case has been made that actinic keratosis is the earliest manifestation of squamous cell carcinoma and should be regarded as such rather than as a precancerous lesion.[28, 29] Others have argued that calling actinic keratosis a carcinoma unduly alarms patients.

Previous
Next

Frequency

United States

Actinic keratosis occurs primarily in whites, the frequency of which correlates with cumulative UV exposure.[5] Therefore, frequency increases with age, proximity to the equator, and outdoor occupation. Actinic keratoses are seen more in men than in women and have also been correlated with a high-fat diet.[4, 30] Overall, the rate in the United States is estimated to range from 11-26%.[21]

International

The prevalence is highest in Australia, where a light-skinned population is common and outdoor sports are very popular activities.[31] Overall, actinic keratosis is estimated to be present in 40-60% of the Australian population older than 40 years.[21]

Race

The prevalence of actinic keratosis is much higher in individuals with fair skin and blue eyes and is lower in individuals with darker skin types.[4] Actinic keratosis is relatively nonexistent in black skin.[32] Patients with actinic keratoses tend to have Fitzpatrick type I or II skin, which burns and does not tan.[5] The prevalence is reduced precipitously in persons with Fitzpatrick types III, IV, and V skin and is nonexistent in those with Fitzpatrick type VI skin.[32] Although the incidence of cutaneous malignancies in darker-skinned individuals is much lower than in white persons, UV exposure may still play a role in the etiology of squamous and basal cell carcinoma; screening and sun safety education should still be promoted because cutaneous malignancies in darker-skinned individuals can be very aggressive.[32]

Sex

The prevalence of actinic keratosis is higher in men than in women.[5] This is theorized to result from a greater likelihood that men have an outdoor occupation and thus have greater cumulative UV exposure.[4]

Age

One of the most important determinants of actinic keratosis risk is age, particularly when evaluated with other strong predictors, including cumulative sun exposure, place of birth, occupation, and skin type.[5, 4] Actinic keratoses can occur in patients aged 20-30 years, but they are more common in patients aged 50 years and older.[5]

Previous
Next

Mortality/Morbidity

Lesions begin as barely perceivable rough spots of skin, better felt than seen.[1, 10] Early lesions feel like sandpaper; later lesions become erythematous, scaly plaques that may enlarge to several centimeters.[5, 1] Lesions may remain unchanged for years, may spontaneously regress, or may progress to invasive squamous cell carcinoma.[23] Most actinic keratoses do not progress to invasive squamous cell carcinoma; however, most invasive squamous cell carcinomas have evidence of a preexisting actinic keratosis.[5, 23] Invasive squamous cell carcinoma may produce significant morbidity by direct extension into facial structures. In less than 10% of cases, invasive squamous cell carcinoma may metastasize, with a low 5-year survival rate.[33, 34]

Previous
Next

Prognosis

The prognosis for actinic keratosis is good. With continuing surveillance and treatment, these lesions can be managed individually. The opportunity for them to develop into invasive squamous cell carcinomas can be prevented by aggressive therapy and sun protection. However, the prognosis in a person with long-term exposure is more guarded because of the multitude of their lesions. Some lesions may progress and develop into invasive squamous cell carcinomas.[18, 23] Patients with extensive involvement unresponsive to cryosurgery and topical therapy may benefit from skin resurfacing by dermabrasion,[17] chemical peeling, or laser resurfacing.[16]

Previous
Next

Patient Education

Encourage patients to wear sunscreens, to limit sun exposure, and to adjust their hobby or profession to decrease sun exposure. For patient education resources, see the Skin Conditions & Beauty Center. Additionally, see the patient education article Skin Cancer.

Previous
 
 
Contributor Information and Disclosures
Author

James M Spencer, MD Professor of Clinical Dermatology, Mount Sinai School of Medicine; Private Practice, Spencer Dermatology

James M Spencer, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American College of Mohs Surgery, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, International Society for Dermatologic Surgery

Disclosure: Received grant/research funds from Genentech for independent contractor; Received grant/research funds from DUSA for independent contractor; Received honoraria from Leo Pharmicuticals for review panel membership.

Coauthor(s)

Laura Jordan, DO, MA, MS, MLS Dermatology-Focus Traditional Rotating Intern, UH Regional Hospitals

Laura Jordan, DO, MA, MS, MLS is a member of the following medical societies: American Osteopathic College of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael J Wells, MD, FAAD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Kelly M Cordoro, MD Assistant Professor of Clinical Dermatology and Pediatrics, Department of Dermatology, University of California, San Francisco School of Medicine

Kelly M Cordoro, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Medical Society of Virginia, Society for Pediatric Dermatology, Women's Dermatologic Society, Association of Professors of Dermatology, National Psoriasis Foundation, Dermatology Foundation

Disclosure: Nothing to disclose.

Michelle Henry, MD Fellow in Procedural Dermatology, Department of Dermatology, Lahey Clinic, Harvard Medical School

Disclosure: Nothing to disclose.

Acknowledgements

Amy Lynn Basile, DO, MPH Sun Coast Hospital/Largo Medical Center, Largo, Florida

Disclosure: Nothing to disclose.

Mary Farley, MD Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center

Disclosure: Nothing to disclose.

James Fulton Jr, MD, PhD Medical Director, Fulton Skin Institute

Disclosure: Nothing to disclose.

References
  1. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol. 2007 Dec. 157 Suppl 2:18-20. [Medline].

  2. Schwartz RA. Premalignant keratinocytic neoplasms. J Am Acad Dermatol. 1996 Aug. 35(2 Pt 1):223-42. [Medline].

  3. Schwartz RA, Bridges TM, Butani AK, Ehrlich A. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol. 2008 May. 22(5):606-15. [Medline].

  4. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998 Dec. 139(6):1033-9. [Medline].

  5. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):4-7. [Medline].

  6. Franceschi S, Levi F, Randimbison L, La Vecchia C. Site distribution of different types of skin cancer: new aetiological clues. Int J Cancer. 1996 Jul 3. 67(1):24-8. [Medline].

  7. James C, Crawford R, Martika M. Actinic Keratosis. James C, Crawford R, Martika M, Marks R, eds. WHO Pathology and Genetics, Skin Tumors. Lyon: IARC Press; 2006. 30-33.

  8. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol. 2002 May. 146(5):810-5. [Medline].

  9. Marks VJ. Actinic keratosis. A premalignant skin lesion. Otolaryngol Clin North Am. 1993 Feb. 26(1):23-35. [Medline].

  10. Sanmartin O, Guillen C. Images in clinical medicine. Fluorescence diagnosis of subclinical actinic keratoses. N Engl J Med. 2008 May 8. 358(19):e21. [Medline].

  11. Spencer JM, Hazan C, Hsiung SH, Robins P. Therapeutic decision making in the therapy of actinic keratoses. J Drugs Dermatol. 2005 May-Jun. 4(3):296-301. [Medline].

  12. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod. Cutis. 2003 May. 71(5):365-70. [Medline].

  13. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids. Cutis. 2003 May. 71(5):373-9. [Medline].

  14. Fuchs J, Thiele J. The role of oxygen in cutaneous photodynamic therapy. Free Radic Biol Med. 1998 Mar 15. 24(5):835-47. [Medline].

  15. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006 Aug. 142(8):976-82. [Medline].

  16. Sherry SD, Miles BA, Finn RA. Long-term efficacy of carbon dioxide laser resurfacing for facial actinic keratosis. J Oral Maxillofac Surg. 2007 Jun. 65(6):1135-9. [Medline].

  17. Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol. 1986 Apr. 14(4):661-8. [Medline].

  18. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):23-4. [Medline].

  19. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):18-22. [Medline].

  20. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992 Aug 21. 70(4):523-6. [Medline].

  21. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994 Oct. 131(4):455-64. [Medline].

  22. Feldman SR, Fleischer AB Jr, McConnell RC. Most common dermatologic problems identified by internists, 1990-1994. Arch Intern Med. 1998 Apr 13. 158(7):726-30. [Medline].

  23. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988 Apr 9. 1(8589):795-7. [Medline].

  24. Backvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F. Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res. 2005 Apr 1. 571(1-2):65-79. [Medline].

  25. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 1994 Sep 30. 85(1):23-9. [Medline].

  26. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004 May-Jun. 22(3):189-96. [Medline].

  27. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007 Sep. 33(9):1099-101. [Medline].

  28. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):11-7. [Medline].

  29. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006 Jul. 155(1):9-22. [Medline].

  30. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994 May 5. 330(18):1272-5. [Medline].

  31. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995 Jan. 32(1):95-8. [Medline].

  32. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006 Nov. 55(5):741-60; quiz 761-4. [Medline].

  33. Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol. 2006 Jun. 142(6):755-8. [Medline].

  34. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992 Jun. 26(6):976-90. [Medline].

  35. Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med. 2005 Dec 22. 353(25):2712-3. [Medline].

  36. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer. 1990 Sep 15. 46(3):356-61. [Medline].

  37. Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005 Jul. 125(1):93-7. [Medline].

  38. McBride P, Neale R, Pandeya N, Green A. Sun-related factors, betapapillomavirus, and actinic keratoses: a prospective study. Arch Dermatol. 2007 Jul. 143(7):862-8. [Medline].

  39. Pfister H, Fuchs PG, Majewski S, Jablonska S, Pniewska I, Malejczyk M. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res. 2003 Dec. 295(7):273-9. [Medline].

  40. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):8-10. [Medline].

  41. Pock L, Drlik L, Hercogova J. Dermatoscopy of pigmented actinic keratosis--a striking similarity to lentigo maligna. Int J Dermatol. 2007 Apr. 46(4):414-6. [Medline].

  42. Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol. 2008 Jan. 7(1):23-5. [Medline].

  43. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993 Oct 14. 329(16):1147-51. [Medline].

  44. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970 Feb. 101(2):132-9. [Medline].

  45. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005 Oct. 9(5):209-14. [Medline].

  46. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002 Jun. 24(6):990-1000. [Medline].

  47. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006 Feb. 5(2):133-9. [Medline].

  48. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007 Dec. 157 Suppl 2:41-6. [Medline].

  49. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010 Apr. 62(4):573-81. [Medline].

  50. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007 Dec. 157 Suppl 2:25-31. [Medline].

  51. Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006 Aug. 155(2):451-4. [Medline].

  52. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012 Mar 15. 366(11):1010-9. [Medline].

  53. Garbe C, Basset-Seguin N, Poulin Y, et al. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study. Br J Dermatol. 2016 Mar. Vol 174(3):505-13. [Medline].

  54. Augustin M, Tu JH, Knudsen KM, Erntoft S, Larsson T, Hanke CW. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015 May. Vol 72(5):816-21. [Medline].

  55. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2011 Nov 4. [Medline].

  56. Boggs W. Ingenol Mebutate Gel Effective for Actinic Keratoses. Medscape. Mar 28 2013. Available at http://Available at: http://www.medscape.com/viewarticle/781629. Accessed: April 8, 2013.

  57. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013 Jun. 149(6):666-70. [Medline].

  58. Jim On SC, Haddican M, Yaroshinsky A, Singer G, Lebwohl M. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis. Cutis. 2015 Jan. 95(1):47-51. [Medline].

  59. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008 Jul. 7(7):669-73. [Medline].

  60. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999 Sep. 41(3 Pt 1):414-8. [Medline].

  61. Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol. 2014 Dec. 150(12):1281-8. [Medline].

  62. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007 Jan. 56(1):125-43. [Medline].

  63. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008 May. 158(5):994-9. [Medline].

  64. McLoone N, Donnelly RF, Walsh M, et al. Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol Photoimmunol Photomed. 2008 Aug. 24(4):183-90. [Medline].

  65. Tarstedt M, Gillstedt M, Wennberg Larkö AM, Paoli J. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers. J Eur Acad Dermatol Venereol. 2016 Mar. Vol 30(3):420-23. [Medline].

  66. Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol. 2012 Jan. Vol 166(1):137-46. [Medline].

  67. Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2013 Apr. Vol 168(4):825-36. [Medline].

  68. Gholam P, Weberschock T, Denk K, Enk A. Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology. 2011. Vol 222(4):358-62. [Medline].

  69. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004 Sep. 43(9):687-92. [Medline].

 
Previous
Next
 
Actinic keratosis. Courtesy of Hon Pak, MD.
Actinic keratosis during treatment with topical 5-fluorouracil. Courtesy of Hon Pak, MD.
Actinic keratosis right after treatment with topical 5-fluorouracil. Courtesy of Hon Pak, MD.
Erythematous, scaly lesions on the temple area, typical of actinic keratosis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.